A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants

NCT06186622 · Completed

Last updated 2026-05-28

This study tests how a new drug, orforglipron, interacts with simvastatin in healthy overweight or obese adults.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) basic-science study

Participants 50 people

Who can join Ages 18–70 · all sexes Healthy volunteers accepted.

Timeline Started 2024-01 · est. completion 2024-07

Where 2 sites · United States

What this study is testing ClinicalTrials.gov NCT06186622 ↗

Description as written by the study sponsor.

The main purpose of this study is to determine effect of orforglipron capsule formulation on the amount of digoxin, rosuvastatin, acetaminophen, midazolam, and simvastatin (each given alone and together with orforglipron) that enters the bloodstream and how long it takes the body to eliminate them when administered orally in healthy overweight and obese participants. In addition, the effect of the orforglipron tablet on the amount of simvastatin that enters the bloodstream and how long it takes the body to eliminate it will be evaluated. The study will also assess the effect of sodium bicarbonate when administered alone with simvastatin versus orforglipron capsule containing sodium bicarbonate administered with simvastatin. The safety and tolerability of orforglipron and information about any side effects experienced will be collected. Study will be conducted in two parts, with part 1 and 2 lasting up to approximately 23 and 24 weeks each, including the screening period.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally.
Simvastatin Drug

Administered orally.
Digoxin Drug

Administered orally.
Rosuvastatin Drug

Administered orally.
Acetaminophen Drug

Administered orally.
Midazolam Drug

Administered orally.
Sodium Bicarbonate Drug

Administered orally.

Main thing measured	Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC[0-∞]) of Simvastatin and Its Metabolite Simvastatin Acid Following Simultaneous Administration of Orforglipron Capsule Formulation (Cohort 1 and 2)
Sponsor	Eli Lilly and Company
Conditions studied	Healthy, Obese, Overweight
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06186622 ↗